Zentalis Pharmaceuticals (ZNTL) Other Non-Current Assets (2019 - 2026)

Zentalis Pharmaceuticals' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 55.88% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 55.88% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 1.04% from the prior year.
• Other Non-Current Assets rose to $4.1 million in Q1 2026 per ZNTL's latest filing, from $2.6 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $4.1 million in Q1 2026 and bottomed at $2.6 million in Q4 2024.
• The 5-year median for Other Non-Current Assets is $2.6 million (2022), against an average of $2.8 million.
• Across the five-year window, Other Non-Current Assets declined 19.52% in 2022 and jumped 55.88% in 2026, its largest moves.
• Year by year, Other Non-Current Assets stood at $2.6 million in 2022, then rose by 2.06% to $2.7 million in 2023, then retreated by 3.02% to $2.6 million in 2024, then grew by 1.04% to $2.6 million in 2025, then jumped by 55.88% to $4.1 million in 2026.
• Per Business Quant, the three latest ZNTL Other Non-Current Assets figures stand at $4.1 million (Q1 2026), $2.6 million (Q4 2025), and $3.2 million (Q3 2025).